ELTX - CIK 0001601485
The table below shows Elicio Therapeutics, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $14.95M | $20.61M | $22.09M | $18.35M | $26.02M | $3.42M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $16.20M |
| $21.46M |
| $22.60M |
| $20.93M |
| $30.65M |
| $6.69M |
| Property, plant & equipment | $249.00K | $328.00K | $377.00K | $430.00K | $523.00K | $597.00K |
| Goodwill | - | - | - | - | - | - |
| Total assets | $22.69M | $28.28M | $29.53M | $28.14M | $38.39M | $15.75M |
| Accounts payable | $272.00K | $321.00K | $3.87M | $4.04M | $1.98M | $1.05M |
| Total current liabilities | $7.23M | $6.51M | $9.92M | $11.41M | $9.02M | $7.58M |
| Long-term debt | $9.47M | $9.72M | $9.34M | - | - | - |
| Total liabilities | $24.13M | $24.47M | $27.69M | $19.24M | $57.37M | $17.40M |
| Retained earnings | -$245.50M | -$225.95M | -$215.87M | -$205.31M | -$180.10M | -$161.26M |
| Total equity | -$1.44M | $3.82M | $1.83M | $8.90M | -$18.99M | -$1.65M |